The genomics firm reaffirmed its $78M to $80M revenue guidance for 2026 while targeting higher clinical test volumes.
Personalis outlined a 2026 clinical test volume target of 43,000 to 45,000, aligning with its previously stated revenue guidance of $78M to $80M. The company framed the year as one of execution, emphasizing scaling efforts for its NeXT Personal product.
In Q1 2026, management highlighted market disruption in minimal residual disease (MRD) testing, reinforcing confidence in its strategy. The revenue guidance remains unchanged from prior projections, reflecting steady growth expectations.
No immediate market reaction was detailed in the source.